X
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSK
https://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
Chiesi
Europe: thumbs up for Roche’s Hemlibra, Chiesi rare disease drug, bad news for Santhera
Drug has been approved in US since November
COPD triple approved, can GSK maximise its revenues?
EU regulators also backed Trelegy
Verona pushes on with COPD drug after £70m fundraiser
UK biotech hopes RPL554 could be a disease modifying drug.
Chiesi backs up COPD triple therapy with real world study
Italian firm takes on mighty GSK
European regulators back Chiesi COPD triple therapy
Chiesi takes on Seretide and other lung drugs with Trimbow.